Literature DB >> 8703645

Resolution of ACE inhibitor cough: changes in subjective cough and responses to inhaled capsaicin, intradermal bradykinin and substance-P.

W W Yeo1, I G Chadwick, M Kraskiewicz, P R Jackson, L E Ramsay.   

Abstract

1. In eight hypertensive patients with ACE inhibitor-induced cough the resolution of the cough was examined in a prospective observational study over 4 weeks duration. Resolution of cough was measured by visual analogue scales and questionnaire at baseline and days 3, 7, 14 and 28. In addition changes in cough sensitivity to inhaled capsaicin, and skin responses to bradykinin and substance-P were measured at the same time points. 2. All patients recorded significant subjective improvement in cough questionnaire scores for severity and night time waking, and by visual analogue scales for severity and frequency of cough (all P < 0.0005 for trend from day 0-28). Significant changes in subjective measures were recorded by 3 to 7 days for most measures, but further reductions were observed up to day 28 (all P < 0.01 day 28 vs day 0). 3. The sensitivity to inhaled capsaicin fell over the 28 days of study after stopping enalapril. The potency of capsaicin relative to day 0 was reduced to 0.25 (95% CI 0.07-0.87) by day 14, and to 0.20 (95% CI 0.06-0.67) by 28 days. 4. After stopping enalapril there was a highly significant reduction in wheal area produced by intradermal bradykinin, with the majority of the effect seen by day 3 (P < 0.0005). The wheal area to intradermal substance-P also declined with time after stopping enalapril, but significant changes were not observed until 14 days (P < 0.01). 5. Multiple regression analysis of the rates of decline for the subjective and objective measures of cough showed significant associations between the response to inhaled capsaicin and the VAS scores for severity of cough (P = 0.005) and frequency of cough (P = 0.011). Capsaicin response was not related significantly to the severity of cough measured by self-administered questionnaire. 6. There was a significant association between bradykinin response and VAS scores for frequency of cough (P < 0.04) and severity of cough (P < 0.05), but not with cough by questionnaire or the capsaicin response. The response to substance-P did not relate significantly to any of the measures of cough. 7. Cough caused by enalapril improved markedly by 14 days but took up to 28 days to resolve. It was associated with increased sensitivity to inhaled capsaicin which decreased over 28 days, and which paralleled changes in subjective cough scores.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8703645      PMCID: PMC1365187     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Angiotensin-converting enzyme inhibition, cough and the serum concentration of substance P.

Authors:  H Thysell; K E Andersson; S I Andersson; R Ekman
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Respiratory effects of angiotensin converting enzyme inhibition.

Authors:  K E Berkin
Journal:  Eur Respir J       Date:  1989-03       Impact factor: 16.671

3.  Increased cough reflex associated with angiotensin converting enzyme inhibitor cough.

Authors:  R W Fuller; N B Choudry
Journal:  Br Med J (Clin Res Ed)       Date:  1987-10-24

4.  Cough associated with captopril and enalapril.

Authors:  D M Coulter; I R Edwards
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-13

5.  The effects of intradermal bradykinin are potentiated by angiotensin converting enzyme inhibitors in hypertensive patients.

Authors:  R E Ferner; D Wilson; J R Paterson; R Wilkinson; M D Rawlins
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

6.  Angiotensin-converting enzyme inhibitor-induced cough.

Authors:  A L Hume; J L Murphy; S E Lauerman
Journal:  Pharmacotherapy       Date:  1989       Impact factor: 4.705

7.  Hydrolysis of substance P and its analogs by angiotensin-converting enzyme from rat lung. Characterization of endopeptidase activity of the enzyme.

Authors:  H Yokosawa; S Endo; Y Ohgaki; J Maeyama; S Ishii
Journal:  J Biochem       Date:  1985-11       Impact factor: 3.387

8.  Effect of dose adjustment on enalapril-induced cough and the response to inhaled capsaicin.

Authors:  W W Yeo; K S Higgins; G Foster; P R Jackson; L E Ramsay
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

9.  Angiotensin-converting enzyme and the cough reflex.

Authors:  A H Morice; R Lowry; M J Brown; T Higenbottam
Journal:  Lancet       Date:  1987-11-14       Impact factor: 79.321

Review 10.  The positive association of cough with angiotensin-converting enzyme inhibitors.

Authors:  P M Just
Journal:  Pharmacotherapy       Date:  1989       Impact factor: 4.705

View more
  9 in total

Review 1.  Cough challenge in the assessment of cough reflex.

Authors:  A H Morice; J A Kastelik; R Thompson
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

2.  Isolated cough: probably not asthma.

Authors:  A B Chang
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

3.  ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?

Authors:  Laura Milazzo; Dario Cattaneo; Stefania Cheli; Laurenzia Ferraris; Elisa Colella; Emilio Clementi; Cristina Gervasoni
Journal:  Eur J Clin Pharmacol       Date:  2012-09-19       Impact factor: 2.953

4.  Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor.

Authors:  Andrew P Davie; John J V McMurray
Journal:  Br J Clin Pharmacol       Date:  2002-01       Impact factor: 4.335

5.  Capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease.

Authors:  M J Doherty; R Mister; M G Pearson; P M Calverley
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 6.  Cough. 1: Chronic cough in adults.

Authors:  A H Morice; J A Kastelik
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

7.  Characteristics and outcomes of patients hospitalized following pulmonary aspiration.

Authors:  Augustine Lee; Emir Festic; Pauline K Park; Krishnan Raghavendran; Ousama Dabbagh; Adebola Adesanya; Ognjen Gajic; Raquel R Bartz
Journal:  Chest       Date:  2014-10       Impact factor: 9.410

8.  ERS guidelines on the diagnosis and treatment of chronic cough in adults and children.

Authors:  Alyn H Morice; Eva Millqvist; Kristina Bieksiene; Surinder S Birring; Peter Dicpinigaitis; Christian Domingo Ribas; Michele Hilton Boon; Ahmad Kantar; Kefang Lai; Lorcan McGarvey; David Rigau; Imran Satia; Jacky Smith; Woo-Jung Song; Thomy Tonia; Jan W K van den Berg; Mirjam J G van Manen; Angela Zacharasiewicz
Journal:  Eur Respir J       Date:  2020-01-02       Impact factor: 16.671

9.  Zofenopril and incidence of cough: a review of published and unpublished data.

Authors:  Stefano Omboni; Claudio Borghi
Journal:  Ther Clin Risk Manag       Date:  2011-11-29       Impact factor: 2.423

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.